{"created":"2023-05-15T12:36:18.405478+00:00","id":143,"links":{},"metadata":{"_buckets":{"deposit":"0578b874-aae0-4fd6-9bf1-925b95b64c4f"},"_deposit":{"created_by":7,"id":"143","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"143"},"status":"published"},"_oai":{"id":"oai:shonan-ums.repo.nii.ac.jp:00000143","sets":["1"]},"author_link":["421","415","416","414","413","411","417","418","419","412","420"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"134","bibliographicPageStart":"127","bibliographicVolumeNumber":"79","bibliographic_titles":[{},{"bibliographic_title":"Human pathology","bibliographic_titleLang":"en"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed.","subitem_description_type":"Abstract"}]},"item_10004_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed.","subitem_description_type":"Other"}]},"item_10004_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29787820","subitem_relation_type_select":"PMID"}}]},"item_10004_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.humpath.2018.05.009","subitem_relation_type_select":"DOI"}}]},"item_10004_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1532-8392","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Iida, Yuko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"411","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Masuda, Shinobu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"412","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakanishi, Yoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"413","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimizu, Tetsuo","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"414","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishimaki, Haruna","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"415","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahashi, Mai","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"416","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hikichi, Mari","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"417","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maruoka, Shuichiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"418","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Gon, Yasuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"419","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahashi, Noriaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"420","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hashimoto, Shu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"421","nameIdentifierScheme":"WEKO"}]}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Aged","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Biomarkers, Tumor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Case-Control Studies","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cell Differentiation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cell Proliferation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Female","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Immunohistochemistry","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Lung Neoplasms","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Male","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Middle Aged","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Prognosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Reverse Transcriptase Polymerase Chain Reaction","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Small Cell Lung Carcinoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Thyroid Nuclear Factor 1","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.","subitem_title_language":"en"}]},"item_type_id":"10004","owner":"7","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-06-01"},"publish_date":"2020-06-01","publish_status":"0","recid":"143","relation_version_is_last":true,"title":["Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers."],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2023-05-15T12:40:14.974912+00:00"}